Teva to buy U.S. drug developer Auspex for $3.5B

Posted online March 30, 2015 | 6:44 am

Israel's Teva Pharmaceutical Industries said it would buy U.S. drug developer Auspex Pharmaceuticals Inc. for $3.5 billion to boost its portfolio of treatments for the central nervous system.

The world's largest maker of generic drugs, Teva announced it will offer $101 per share in cash, representing a 42.4 percent premium on Auspex's Friday closing price.

The deal is expected to be finalized by 2017.

Read more from Reuters.[[In-content Ad]]

Comments

No comments on this story |

Please log in to add your comment

Council of Churches unveils new name

Editors' Pick

From the Ground Up: Fulbright Heights Apartments

Taking shape on 3.5 acres just east of State Highway H/Glenstone Avenue in the area of Valley Water Mill Park are the Fulbright Heights Apartments – three 23,000-square-foot buildings with 24 units each for a total of 72 one- and two-bedroom apartments.

Most Read